Bringing over 20 years’ experience in private practice, Karen specialises in the fields of life sciences and pharmaceuticals. Having started her career in London, she joined HGF in 2010 and enjoys being an active member of the biotech and chemical teams in the Manchester office.
Karen’s experience covers a wide range of biotechnological and biopharmaceutical subject matter including nucleic acid and peptide based therapeutics. She has a particular interest in SPCs, and her practice includes filing and prosecution of SPC applications in both the medicinal and agrochemical fields.
In the course of her career, she has worked with a variety of clients, including universities, SMEs and large multi-nationals, providing guidance in patent prosecution before the EPO and internationally, as well as advice relating to patentability, freedom to operate, and SPC filings.
Karen holds an MA in Natural Sciences (Biological), and an MPhil in Biotechnology, both from the University of Cambridge. Her MPhil research investigated the genetic basis for the microbial degradation of cocaine.
Natural Sciences (Cantab)
Queen Mary and Westfield College Certificate in Intellectual Property Law
MPhil Biotechnology (Cantab)
November 17th 2020
Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …Event details
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.